Find biotech stocks that can survive -- and potentially thrive -- in market downturns.
There are over 100 biotech companies trading below cash, and many more down 50%+ in the last year.
See which ones will survive the bear market -- and which won't -- with screens for companies trading below or near cash, that have enough runway to wait out the bear market, and more.
What are the highest and lowest valued Phase 2 oncology companies? Which neuro companies are most promising? Screen by therapeutic area and development stage in addition to financial metrics.
Who are the major institutional holders of a stock? Are they buying or selling?
See which companies have strong shareholder bases that can keep cash-burning companies alive.
Which investors are buying and selling early-stage biotech stocks? Who is a long-term holder, and who focuses on short-term flips?
Biotech stock screener
View institutional holders
Institutional investor portfolio summary
Biotech IPO investment activity
M&A and IPO comps
Private investor performance metrics
Deal-level returns for private investments
Investment activity and profiles for thousands of private investors
Private investor fund info, check sizes, exits and recent deals
If you are not satisfied with your purchase, let us know within 14 days for a full refund.
© 2022 Bay Bridge Bio, LLC